FRANKLIN, Tenn. / Feb 21, 2025 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in three investor conferences in March.
On Tuesday, March 4, 2025, the Company will participate in the Raymond James 46th Annual Institutional Investors Conference, being held March 2-5, 2025, in Orlando, Florida. The Company’s presentation will begin at 8:05 a.m. Eastern Time/7:05 a.m. Central Time.
On Tuesday, March 11, 2025, the Company will participate in the Leerink Partners 2025 Global Healthcare Conference, being held March 10-12, 2025, in Miami, Florida. The Company’s presentation will begin at 2:20 p.m. Eastern Time/1:20 p.m. Central Time.
On Wednesday, March 12, 2025, the Company will participate in the Barclays 27th Annual Global Healthcare Conference, being held March 11-13, 2025, in Miami, Florida. The Company’s presentation will begin at 9:30 a.m. Eastern Time/8:30 a.m. Central Time.
The live webcast of all the presentations will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentations will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2024, Acadia operated a network of 260 behavioral healthcare facilities with approximately 11,300 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
| Last Trade: | US$23.84 |
| Daily Change: | -4.85 -16.90 |
| Daily Volume: | 3,865,351 |
| Market Cap: | US$2.210B |
February 27, 2025 October 30, 2024 July 31, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
